Literature DB >> 7068172

Influence of aggregate size on the binding and activation of the first component of human complement by soluble IgG aggregates.

G Doekes, L A Vanes, M R Daha.   

Abstract

The interaction between small aggregates of human IgG and the first component of human complement was studied. Stabilized soluble IgG aggregates of restricted size were prepared by heat aggregation of human IgG, followed by sucrose-density ultracentrifugation. Human C1 was isolated in its precursor form by euglobulin precipitation, followed by gel filtration and immunoadsorption. A C1 preparation was obtained of which more than 90% was still in its unactivated form. Soluble aggregates containing 20, 10 or 5 molecules IgG, and monomeric IgG were tested for their ability to bind and to activate C1. The binding of C1 was determined by C1 consumption, whereas the activation of C1 was measured as the increased ability of the C1 preparation to consume purified human C4 after the incubation with the aggregates. The three aggregates tested and monomeric IgG were all able to bind and to activate C1, but the efficiency of both processes markedly increased with increasing aggregate-size. Furthermore, it was found that all four preparations activated an appreciable amount of C1 at concentrations that did not result in any detectable C1 fixation. These results confirm earlier suggestion that C1 can be activated during a short, transient binding to small aggregates or immune complexes that have a low avidity for C1, after which the activated form, C1, is released into the medium.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7068172      PMCID: PMC1555415     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

1.  Fixation of C' and C'la by rabbit gamma-G- and gamma-M-antibodies with particulate and soluble antigens.

Authors:  T Ishizaka; T Tada; K Ishizaka
Journal:  J Immunol       Date:  1968-06       Impact factor: 5.422

2.  Isolation and characterization of the proenzyme form of the C1r subunit of the first complement component.

Authors:  G Valet; N R Cooper
Journal:  J Immunol       Date:  1974-05       Impact factor: 5.422

3.  Complement fixation on cell surfaces by 19S and 7S antibodies.

Authors:  T Borsos; H J Rapp
Journal:  Science       Date:  1965-10-22       Impact factor: 47.728

4.  The requirement for the association of two adjacent rabbit gamma-G-antibody molecules in the fixation of complement by immune complexes.

Authors:  S Cohen
Journal:  J Immunol       Date:  1968-02       Impact factor: 5.422

5.  The fixation of complement and the activated first component (C1) of complement by complexes formed between antibody and divalent hapten.

Authors:  N E Hyslop; R R Dourmashkin; N M Green; R R Porter
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

6.  Titration of the first component of complement on a molecular basis: suitability of IgM and unsuitability of IgG hemolysins as sensitizer.

Authors:  H R Colten; T Borsos; H J Rapp
Journal:  Immunochemistry       Date:  1969-05

7.  Complement fixation: the effects of IgG and IgM antibody concentration on C1-binding affinity.

Authors:  W D Linscott
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

8.  Isolation and characterization of the proenzyme form of the C1s subunit of the first complement component.

Authors:  G Valet; N R Cooper
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

9.  A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement.

Authors:  T A Gaither; D W Alling; M M Frank
Journal:  J Immunol       Date:  1974-08       Impact factor: 5.422

10.  The reaction of monomeric and aggregated immunoglobulins with C1.

Authors:  W Augener; H M Grey; N R Cooper; H J Müller-Eberhard
Journal:  Immunochemistry       Date:  1971-11
View more
  14 in total

1.  Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Authors:  Michael Huber; Viktor von Wyl; Christoph G Ammann; Herbert Kuster; Gabriela Stiegler; Hermann Katinger; Rainer Weber; Marek Fischer; Heribert Stoiber; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

2.  Effect of medium pH and antibody Fc fragment on the size of model immune complexes.

Authors:  L B Korolevskaya; K V Shmagel; V A Chereshnev
Journal:  Dokl Biochem Biophys       Date:  2014-01-03       Impact factor: 0.788

3.  Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes.

Authors:  Azusa Hashimoto; Yusuke Suzuki; Hitoshi Suzuki; Isao Ohsawa; Rhubell Brown; Stacy Hall; Yuichi Tanaka; Jan Novak; Hiroyuki Ohi; Yasuhiko Tomino
Journal:  Am J Pathol       Date:  2012-08-05       Impact factor: 4.307

4.  Effect of complement on sizes of model immune complexes.

Authors:  L B Korolevskaya; K V Shmagel
Journal:  Dokl Biochem Biophys       Date:  2014-11-04       Impact factor: 0.788

5.  Heterogeneity, polypeptide chain composition and antigenic reactivity of autoantibodies (F-42) that are directed against the classical pathway C3 convertase of complement and isolated from sera of patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; L A van Es
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

6.  Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor.

Authors:  G Doekes; J Schouten; A Cats; M R Daha
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

7.  Differential precipitation of the Clq subcomponent of the first complement component (C1) by polyethylene glycol from normal human serum and sera of patients with collagen diseases.

Authors:  H Van Dijk; J Van Voorst; I G Jankowski; J W Imhof; J A Kerckhaert
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

8.  C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.

Authors:  G Doekes; L A van Es; M R Daha
Journal:  Immunology       Date:  1983-06       Impact factor: 7.397

9.  C1 inactivator-C1s complexes in inflammatory joint disease.

Authors:  R D Inman; P C Harpel
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

10.  In vivo degradation of rat C1q induced by intravenous injection of soluble IgG aggregates.

Authors:  R Veerhuis; L A van Es; M R Daha
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.